Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "SUIT-004 O2 pfi D010"

From Bioblast
Β 
(28 intermediate revisions by 10 users not shown)
Line 1: Line 1:
{{MitoPedia
{{MitoPedia
|abbr=NS(PM)
|abbr=RP1-short pfi
|description=[[File:1PM;2D;2c;3U;4S;5Rot.png|300px]]
|description=[[File:1PM;2D;2c;3U;4S;5Rot;6Ama;7AsTm;8Azd.png|450px]]
|SUIT number=D010_1PM;2D;3U;4S;5Rot;6Ama
|info='''[[SUIT-004]]''' - Short protocol linked to [[SUIT-001 O2 pfi D002]] '''SUIT RP1''' (human skeletal muscle)
|info='''A''': '''[[SUIT-004]]''' short protocol linked to [[SUIT-001 O2 pfi D002]] - '''SUIT RP1''' (human skeletal muscle)
|application=O2
|application=O2
|SUIT number=D010_1PM;2D;2c;3U;4S;5Rot;6Ama;7AsTm;8Azd
}}
}}
::: '''[[Categories of SUIT protocols |SUIT-category]]:''' NS(PM)
{{Template:SUIT text D010}} {{Template:Setting oxygen pfi}}
::: '''[[SUIT protocol pattern]]:''' orthogonal 1PM;2D;2c;3U;4S;5Rot;6Ama
::::* Linked to [[SUIT-001 O2 pfi D002]] - SUIT RP1, specifically for human skeletal muscle mitochondria.
::::* Harmonized with [[SUIT-005 O2 pfi D011]].


__TOC__
Communicated by [[Doerrier C]], [[Gnaiger E]] (last update 2019-06-05)
== Representative traces ==


__TOC__
[[File:SUIT 004.png|600px]]
Communicated by [[Iglesias-Gonzalez J]] and [[Gnaiger E]] (last update 2019-01-21)
== References ==
{{#ask:[[Category:Publications]] [[Additional label::SUIT-004 O2 pfi D010]]
| ?Was published in year=Year
| ?Has title=Reference
| ?Mammal and model=Organism
| ?Tissue and cell=Tissue;cell
| format=broadtable
| limit=5000
| offset=0
| sort=Was published in year
| order=descending
}}


{{Template:SUIT-004}}
{{Template:SUIT-004}}
Line 31: Line 18:
== Strengths and limitations ==
== Strengths and limitations ==


:::* SUIT-001 in combination with [[SUIT-002]] provides a common reference for comparison of respiratory control in a large variety of species, tissues and cell types. Both SUIT protocols provide a mitochondrial mapping which allows:
:::: 1. to obtain reference values.
:::: 2. to evaluate mitochondrial physiological diversity, generating a mt-database on comparative mitochondrial physiology.
:::: 3. to screen specific defects.
:::* SUIT-001 and [[SUIT-002]] are used in the [[Proficiency_test| MitoFit Proficiency test]] for inter-individual and inter-laboratory reproducibility quality control.
:::* A succinate concentration of >10 mM may be required for saturating S<sub>''E''</sub> capacity.
:::* A succinate concentration of >10 mM may be required for saturating S<sub>''E''</sub> capacity.
Β 
::::* CIV assessment is skipped if a prolonged protocol is not practical due to time limitation.
:::+ Linear coupling control (''L''-''P''-''E'') with N substrates (PM).
::::# '''RP1-6Ama''' may be skipped since correction of the initial states by ROX measured in RP1-6 Ama may represent an over-correction, and inhibition takes a very long time in several cases ([[Pesta 2012 Methods Mol Biol]]).
:::+ Pathway control in ET state (N, NS, FNS, S and SGp pathways).
:::+ Linear coupling control ([[LEAK respiration|''L'']]-[[Oxidative phosphorylation| ''P'']]-[[ET capacity| ''E'']]) with NADPH-linked substrate substrates ([[PM-pathway control state|PM]]).
:::+ Harmonization with [[SUIT-002]] allows to perform both SUIT protocols in parallel. The cross-linked respiratory states can be statically used as repeat measurements.
:::+ Pathway control in ET state ([[NADH_Electron_transfer-pathway_state|N]], [[NS-pathway control state| NS]], [[Succinate pathway control state| S]]).
:::+ In mtprep, SUIT-001 and SUIT-002 harmonize in: SGp<sub>''E''</sub> (8Gp in SUIT-001 and 10Rot in SUIT-002) and Complex IV.
:::+ Harmonization with many SUIT protocols (up to step 5S).
:::+ Oct is added in ET state to avoid uncoupler effect with fatty acids.
:::+ If NS- and FNS-pathways are similar (NS<sub>''E''</sub> ~ FNS<sub>''E''</sub>), the additivity index of N- and S-pathways in ET state can be evaluated. Β 
:::+ This protocol can be extended with the Complex IV module.
:::+ This protocol can be extended with the Complex IV module.
Β 
:::+ Short experimental time.
:::- The substrate combination for maximum ET capacity (FNSGP) is not obtained in SUIT-001 in favour of measuring S<sub>''E''</sub>.
:::- The substrate combination for maximum ET capacity (FNSGP) is not obtained in SUIT-004 in favor of reducing the time consumed during the experiment.


== Compare SUIT protocols ==
== Compare SUIT protocols ==


:::* [[SUIT-001 O2 pfi D002]]: A comparable but more comprehensive protocol comprising additional substrate states.
:::* Harmonized with [[SUIT-005 O2 pfi D011]].
:::'''Specific cases'''
:::'''Specific cases'''
::::* [[Isolated mitochondria |imt]], ROX: NS(PM)01_imt,1PM,2D(c),3U,4S,5Rot,6Ama
::::* [[Isolated mitochondria |imt]], ROX: NS(PM)01_imt,1PM,2D(c),3U,4S,5Rot,6Ama
::::* [[Permeabilized muscle fibres |pfi]], high O<sub>2</sub>, no ROX: NS(PM)01_pfiO2,1PM,2D(c),3U,4S,5Rot
::::* [[Permeabilized muscle fibers |pfi]], high O<sub>2</sub>, no ROX: NS(PM)01_pfiO2,1PM,2D(c),3U,4S,5Rot
Β 
== Chemicals and syringes ==
{{Template:Chemicals SUIT-004}}
{{Template:Chemicals CIV}}
::: Suggested stock concentrations are shown in the specific DL-Protocol.


::::* The '''[[SUIT-004]]''' protocol is linked to [[SUIT-001 O2 pfi D002]] for healthy human skeletal muscle mitochondria on the basis of the following rationale.
== References ==
{{#ask:[[Category:Publications]] [[Additional label::SUIT-004 O2 pfi D010]]
| ?Was published in year=Year
| ?Has title=Reference
| ?Mammal and model=Organism
| ?Tissue and cell=Tissue;cell
| format=broadtable
| limit=5000
| offset=0
| sort=Was published in year
| order=descending
}}


::::# The first coupling control steps (1-4) are identical.
::::# '''RP1-5G''' is skipped, since [[PM]] and [[PGM]] yield nearly identical OXPHOS capacity. However, [[PM]]<[[PGM]] is a potential diagnostic for a defect in the PM-linked pathway upstream of CI.
::::# '''RP1-7Oct''' is skipped, since octanoylcarnitine exerts practically no stimulatory effect on OXPHOS capacity in state [[PMS]] or [[PGMS]], but in conjunction with prolonged exposure may even yield a slight decline of respiration.
::::# '''RP1-9Gp''' is skipped, since glycerolphosphate exerts only a minor stimulatory effect on OXPHOS capacity in state [[SRot]].
::::# Omission of the three steps described above shortens the SUIT protocol, thus reducing the risk of diminishing respiratory capacity over time, reducing the number of necessary reoxygenations, and providing more time for detailed evaluation of steady-states. The loss of diagnostic information may be minor relative to the benefits of simplification of the protocol, particularly in studies of exercise in healthy humans.
::::# '''RP1-10Ama''' may be skipped, since correction of the initial states by ROX measured in RP1-10 Ama may represent an over-correction, and inhibition takes a very long time in several cases ([[Pesta 2012 Methods Mol Biol]]).
::::# '''RP1-11Tm''' and '''RP1-12Azd''' are skipped, if a prolonged protocol is not practical due to limination of time.


{{MitoPedia concepts
{{MitoPedia concepts

Latest revision as of 23:49, 12 April 2021


high-resolution terminology - matching measurements at high-resolution


SUIT-004 O2 pfi D010

Description

1PM;2D;2c;3U;4S;5Rot;6Ama;7AsTm;8Azd.png

Abbreviation: RP1-short pfi

Reference: SUIT-004 - Short protocol linked to SUIT-001 O2 pfi D002 SUIT RP1 (human skeletal muscle)

SUIT number: D010_1PM;2D;2c;3U;4S;5Rot;6Ama;7AsTm;8Azd

O2k-Application: O2

The SUIT-004 O2 pfi D010 protocol provides information of the linear coupling control (L- P- E) with NADH linked-substrates (PM). Moreover, the pathway control in ET state (N, NS and S) can be evaluated by using this SUIT protocol. The SUIT-004 O2 pfi D010 can be extended with the CIV assay module. Permeabilized muscle fibers are sensitive to oxygen supply due to limited diffusion of oxygen to the fiber bundle core. To counteract this limitation, hyperoxic conditions (400-250 Β΅M O2) must be employed. To set the optimal oxygen concentration in the O2k-Chamber, see Setting the oxygen concentration.

Communicated by Doerrier C, Gnaiger E (last update 2019-06-05)

Representative traces

SUIT 004.png

MitoPedia: SUIT

Steps and respiratory states

1PM;2D;2c;3U;4S;5Rot;6Ama;7AsTm;8Azd.png

Step State Pathway Q-junction Comment - Events (E) and Marks (M)
1PM PML(n) N CI 1PM
2D PMP N CI 1PM;2D
2c PMcP N CI 1PM;2D;2c
3U PME N CI 1PM;2D;3U
4S PMSE NS CI&II 1PM;2D;3U;4S
  • Respiratory stimulation by simultaneous action of type N substrates & succinate, with convergent electron flow in the NS-pathway for reconstitution of TCA cycle function.
  • Noncoupled electron transfer state, ET state, with ET capacity E.
5Rot SE S CII 1PM;2D;3U;4S;5Rot
6Ama ROX 1PM;2D;3U;4S;5Rot;6Ama
  • Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated after addition of antimycin A (inhibitor of CIII). Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration (mt).
Step Respiratory state Pathway control ET-Complex Comment
## AsTm AsTmE CIV CIV
## Azd CHB


Questions.jpg


Click to expand or collaps
Bioblast links: SUIT protocols - >>>>>>> - Click on [Expand] or [Collapse] - >>>>>>>

Strengths and limitations

  • A succinate concentration of >10 mM may be required for saturating SE capacity.
  • CIV assessment is skipped if a prolonged protocol is not practical due to time limitation.
  1. RP1-6Ama may be skipped since correction of the initial states by ROX measured in RP1-6 Ama may represent an over-correction, and inhibition takes a very long time in several cases (Pesta 2012 Methods Mol Biol).
+ Linear coupling control (L- P- E) with NADPH-linked substrate substrates (PM).
+ Pathway control in ET state (N, NS, S).
+ This protocol can be extended with the Complex IV module.
+ Short experimental time.
- The substrate combination for maximum ET capacity (FNSGP) is not obtained in SUIT-004 in favor of reducing the time consumed during the experiment.

Compare SUIT protocols

Specific cases
  • imt, ROX: NS(PM)01_imt,1PM,2D(c),3U,4S,5Rot,6Ama
  • pfi, high O2, no ROX: NS(PM)01_pfiO2,1PM,2D(c),3U,4S,5Rot

Chemicals and syringes

Step Chemical(s) and link(s) Comments
1PM Pyruvate (P) and Malate (M)
2D ADP (D)
2c Cytochrome c (c)
3U Carbonyl cyanide m-chlorophenyl hydrazone, CCCP (U) Can be substituted for other uncoupler
4S Succinate (S)
5Rot Rotenone (Rot)
6Ama Antimycin A (Ama)
Step Chemical(s) and link(s) Comments
## AsTm Ascorbate (As) and TMPD (Tm)
## Azd Azide (Azd)
Suggested stock concentrations are shown in the specific DL-Protocol.

References

MitoPedia concepts: SUIT protocol, SUIT A, Find 


MitoPedia methods: Respirometry